Loading...
Novel therapies that target vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways have transformed that manner in which patients with advanced renal cancer are managed; but because these agents are not curative, disease progression eventually ensues. Data on optimal sequential use of these therapies are lacking, and efforts to explore combined use of targeted agents have been hampered by intolerable toxicities.
Evidence suggests that the VEGF inhibitor bevacizumab and the mTOR inhibitor everolimus can be given concurrently without dose reductions; therefore, investigators assessed this combination in a partially manufacturer-supported, phase II multicenter trial involving 80 patients with biopsy-proven m…